Market Cap 555.25M
Revenue (ttm) 0.00
Net Income (ttm) -129.47M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.01
Volume 1,137,000
Avg Vol 1,235,788
Day's Range N/A - N/A
Shares Out 68.63M
Stochastic %K 31%
Beta 2.08
Analysts Strong Sell
Price Target $24.38

Company Profile

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivota...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 651 3316
Website: olema.com
Address:
780 Brannan Street, San Francisco, United States
theBigDollarski
theBigDollarski Oct. 21 at 11:59 AM
$OLMA i was waiting for a pullback and got it..I'm in
0 · Reply
DaBullRunner
DaBullRunner Oct. 20 at 8:29 PM
BYND there it goes… TOLD YOU👇🤑💰🤑💰🤑 RVP adding this before the crowd arrives 🚨🚨🚨 Adding with the CEO 🚢📦📦📦 This could be the next OPEN I’m telling you And I got in this EARLY $CHNR $JWEL $OLMA $OSRH $GIFT let’s get it
0 · Reply
Gabu
Gabu Oct. 20 at 5:40 PM
$OLMA Market is discounting it and favoring Roche but the data is very positive.
0 · Reply
mikelet
mikelet Oct. 20 at 1:28 PM
$OLMA I understand results are good for 120mg, isn't it?
2 · Reply
OpenOutcrier
OpenOutcrier Oct. 20 at 12:23 PM
$OLMA (-30.1% pre) 15.5‑Month Median PFS — Olema Oncology's 120 mg palazestrant + ribociclib supports Phase 3 OPERA-02 https://ooc.bz/l/81151
0 · Reply
JarvisFlow
JarvisFlow Oct. 20 at 11:58 AM
HC Wainwright & Co. updates rating for Olema Pharmaceuticals ( $OLMA ) to Buy, target set at 28.
0 · Reply
justiceforb_85
justiceforb_85 Oct. 19 at 4:03 AM
$OLMA palezsatrant likely best-in-class and active in ESR1-WT patients.
1 · Reply
microeone
microeone Oct. 18 at 4:37 PM
$OLMA good data release albeit phase 1/2… continue to show pala might be best in class
1 · Reply
Quantumup
Quantumup Oct. 8 at 3:46 PM
Guggenheim🏁 $OLMA Buy/$20 $NVS $PFE $RHHBY Guggenheim said in it initiation report:
0 · Reply
FormFour
FormFour Oct. 5 at 3:33 PM
$OLMA Healthcare technology. Testing key support. Volume pattern shows distribution. Growth concerns persisting.
0 · Reply
Latest News on OLMA
Olema Oncology to Participate in Upcoming Investor Conferences

Aug 20, 2025, 4:30 PM EDT - 2 months ago

Olema Oncology to Participate in Upcoming Investor Conferences


Olema Oncology Appoints Shawnte M. Mitchell, J.D.

Feb 18, 2025, 7:00 AM EST - 8 months ago

Olema Oncology Appoints Shawnte M. Mitchell, J.D.


Top 3 Health Care Stocks That May Explode In Q4

Dec 18, 2024, 7:46 AM EST - 11 months ago

Top 3 Health Care Stocks That May Explode In Q4

SLN


Olema Pharmaceuticals: Advancing On Multiple Fronts

Nov 28, 2023, 11:52 AM EST - 2 years ago

Olema Pharmaceuticals: Advancing On Multiple Fronts


Olema: Two-Pronged Approach To Treat Breast Cancer Patients

Sep 18, 2023, 3:20 PM EDT - 2 years ago

Olema: Two-Pronged Approach To Treat Breast Cancer Patients


Olema Oncology: Best Contrarian Oncology Play For 2023

May 19, 2023, 4:30 PM EDT - 2 years ago

Olema Oncology: Best Contrarian Oncology Play For 2023


theBigDollarski
theBigDollarski Oct. 21 at 11:59 AM
$OLMA i was waiting for a pullback and got it..I'm in
0 · Reply
DaBullRunner
DaBullRunner Oct. 20 at 8:29 PM
BYND there it goes… TOLD YOU👇🤑💰🤑💰🤑 RVP adding this before the crowd arrives 🚨🚨🚨 Adding with the CEO 🚢📦📦📦 This could be the next OPEN I’m telling you And I got in this EARLY $CHNR $JWEL $OLMA $OSRH $GIFT let’s get it
0 · Reply
Gabu
Gabu Oct. 20 at 5:40 PM
$OLMA Market is discounting it and favoring Roche but the data is very positive.
0 · Reply
mikelet
mikelet Oct. 20 at 1:28 PM
$OLMA I understand results are good for 120mg, isn't it?
2 · Reply
OpenOutcrier
OpenOutcrier Oct. 20 at 12:23 PM
$OLMA (-30.1% pre) 15.5‑Month Median PFS — Olema Oncology's 120 mg palazestrant + ribociclib supports Phase 3 OPERA-02 https://ooc.bz/l/81151
0 · Reply
JarvisFlow
JarvisFlow Oct. 20 at 11:58 AM
HC Wainwright & Co. updates rating for Olema Pharmaceuticals ( $OLMA ) to Buy, target set at 28.
0 · Reply
justiceforb_85
justiceforb_85 Oct. 19 at 4:03 AM
$OLMA palezsatrant likely best-in-class and active in ESR1-WT patients.
1 · Reply
microeone
microeone Oct. 18 at 4:37 PM
$OLMA good data release albeit phase 1/2… continue to show pala might be best in class
1 · Reply
Quantumup
Quantumup Oct. 8 at 3:46 PM
Guggenheim🏁 $OLMA Buy/$20 $NVS $PFE $RHHBY Guggenheim said in it initiation report:
0 · Reply
FormFour
FormFour Oct. 5 at 3:33 PM
$OLMA Healthcare technology. Testing key support. Volume pattern shows distribution. Growth concerns persisting.
0 · Reply
elmono
elmono Oct. 2 at 3:00 PM
$OLMA high vol up…low vol down…typical accumulation pattern
0 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 11:10 AM
$OLMA: Unusual Options Activity Alerted CALL flow observed 221x contracts at Strike price of $12 Exp on 11/21/2025 with Premium of $31K and showing BULLISH Sentiment
0 · Reply
DARKP00L
DARKP00L Oct. 1 at 5:33 PM
$OLMA momentum building! Stock attracting attention, could be a mover!
0 · Reply
GottaWearShades
GottaWearShades Oct. 1 at 5:15 PM
$OLMA yep. hope you held on.
0 · Reply
EvCe
EvCe Oct. 1 at 3:38 PM
$OLMA congrats to everyone! 🦾 ets keep it up! 🚀
0 · Reply
DarthGoat
DarthGoat Sep. 30 at 5:06 PM
$OLMA OOOOUUUTTT +27% All calls in real time.
0 · Reply
Jacoz
Jacoz Sep. 26 at 6:05 PM
$ATYR $OLMA is a better investment at the moment.
0 · Reply
Filvul
Filvul Sep. 18 at 3:11 PM
$OLMA nicee
0 · Reply
Filvul
Filvul Sep. 15 at 10:20 PM
0 · Reply
ZacksResearch
ZacksResearch Sep. 12 at 2:40 PM
$OLMA surges 46.5% so far in September — what's driving the rally? A new collaboration announcement with $PFE for OLMA's palazestrant in a phase Ib/II study for metastatic breast cancer is propelling the stock higher. This marks their second partnership, highlighting strong potential in the oncology space. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2750842/olma-stock-soars-47-in-september-so-far-on-second-pfe-deal?cid=sm-stocktwits-2-2750842-body-12192&ADID=SYND_STOCKTWITS_TWEET_2_2750842_BODY_12192
0 · Reply
ZacksResearch
ZacksResearch Sep. 12 at 1:40 PM
$OLMA ripping higher — up 47% in September on fresh momentum. The driver? A second Pfizer collaboration tied to its lead breast cancer product candidate, palazestrant. Full breakdown here 👉 https://www.zacks.com/stock/news/2750842/olma-stock-soars-47-in-september-so-far-on-second-pfe-deal?cid=sm-stocktwits-2-2750842-teaser-12191&ADID=SYND_STOCKTWITS_TWEET_2_2750842_TEASER_12191
0 · Reply